Copyright
©The Author(s) 2018.
World J Gastroenterol. Nov 14, 2018; 24(42): 4738-4749
Published online Nov 14, 2018. doi: 10.3748/wjg.v24.i42.4738
Published online Nov 14, 2018. doi: 10.3748/wjg.v24.i42.4738
Biomarker | Cancer type | Expression | Where is it measured? | Treatment | Predictive value | Ref. |
CXCL1/2 | Breast cancer | High | Paraffin embedded tissue | Chemoresistance 5FU | Poor | [17] |
CXCL1 | CRC | High | Tumor and cell lines | OXA + CURCUMIN | Poor | [18] |
CXCL1/8 CXCR2 | CRC, Prostate cancer | High | Cell lines and in vivo | OXA + SCH-527123 | Poor | [22,24] |
CXCL8 | CRC | Low | Serum | Chemotherapy + Bevacizumab | Good | [25,26] |
CXCL8 | Breast cancer | Polymorphism, TT genotype | Peripheral blood (DNA) | FOLFOX+ Bevacizumab vs FOLFOX alone | Good | [26] |
CXCR1 | CRC | Polymorphism | Whole blood (DNA) | OXA based + Bevacizumab | Good | [27] |
CXCL7/8 CXCR2 | CRC | High | mRNA levels tumors | Surgery + ady vs Ady alone | Poor | [28] |
CXCR4 | CRC | Colocalization-Lgr5 | CRC cell lines and tumors | Poor | [35] | |
CXCR4 | CRC | Colocalization-CD133 | CRC cell lines and in vivo | 5FU; 5FU and OXA | Poor | [36,38] |
CXCR4-microbiota | CRC | High | in vivo and in vitro | Lipopolysaccharides | Poor | [39] |
CXCL12-visfatin | CRC | Interaction | CRC cells | Poor | [40] | |
CXCR4 | CRC | High | Paraffin embedded tissue | Patients that underwent hepatectomy | Poor | [41] |
CXCR4 | CRC | High | CRC cells | OXA or 5FU therapies including anti-VEGF | Poor | [46] |
CXCL10-KRAS mut | CRC CMS2 and CMS3 | Low | TCGA, tumors | Poor | [52] | |
CXCL10 | CRC | High | CRC cells, tumors, in vivo | Good | [53] | |
CXCL10 | CRC | Expression | Post-surgical localized CRC | Good | [53,56] | |
CXCR3 | CRC | High | Protein levels in primary tumors | Poor | [57] | |
CXCL10/11 | CRC | High | Serum | Poor | [58] | |
CXCL9/10 | CRC | High | in vivo | Anthracyclines + STAT KO | Good | [60] |
CXCL9/10/11 | Rectal cancer | High | mRNA levels tumors | 5FU + Radiotherapy | Good | [64,65] |
CXCL4 | CRC | High | in vivo | 5FU | Poor | [66] |
CXCL13 CXCR5 | CRC | High | Plasma levels and paraffin embedded tissue | Poor | [69,70] | |
CXCL13-microbiota | CRC | High | Tumors | Good | [71] | |
CXCR5⁺ CD8⁺ T cell | CRC | Presence | Tumors | Good | [73] | |
CXCL13 | CRC | Low | mRNA levels tumors | Good | [56,74] | |
CXCL16 | CRC | High | Serum | Poor | [81] | |
CXCL17 | CRC | High | mRNA levels cell lines and tumors | Poor | [87] |
CXC ligand | Chemokine name | Receptor | ELR domain |
CXCL1 | Growth-regulated oncogene (Gro-α) | CXCR2 | ELR+ |
CXCL2 | Growth-regulated oncogene (Gro-β) | CXCR2 | ELR+ |
CXCL3 | Growth-regulated oncogene (Gro-γ) | CXCR2 | ELR+ |
CXCL4 | Platelet factor-4 (PF-4) | CXCR3 | ELR⁻ |
CXCL5 | Epithelial cell-derived neutrophil-activating peptide-78 (ENA-78) | CXCR2 | ELR+ |
CXCL6 | Granulocyte chemotactic protein-2 (GCP-2) | CXCR1/2 | ELR+ |
CXCL7 | Neutrophil-activating peptide-2 (NAP-2) | CXCR2 | ELR+ |
CXCL8 | Interleukin-8 (IL-8) | CXCR1/2 | ELR+ |
CXCL9 | Monokine induced by interferon-γ (Mig) | CXCR3 | ELR⁻ |
CXCL10 | Inducible protein-10 (IP-10) | CXCR3 | ELR⁻ |
CXCL11 | Interferon-inducible T cell alpha chemoattractant (I-TAC) | CXCR3/7 | ELR⁻ |
CXCL12 | Stromal cell-derived factor-1 (SDF-1) | CXCR4/7 | ELR⁻ |
CXCL13 | B cell-attracting chemokine-1 (BCA-1) | CXCR5 | ELR⁻ |
CXCL16 | Scavenger receptor that binds phosphatidylserine and oxidized lipoprotein (SR-PSOX) | CXCR6 | ELR⁻ |
CXCL17 | VEGF-correlated chemokine-1 (VCC-1) | CXCR8 | ELR+ |
- Citation: Heras SCDL, Martínez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol 2018; 24(42): 4738-4749
- URL: https://www.wjgnet.com/1007-9327/full/v24/i42/4738.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i42.4738